ArticleBiomarkers in medicine2009
Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?
Article in Biomarkers in medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma.Scientific reports · 2023Article
- A perception-based nanosensor platform to detect cancer biomarkers.Science advances · 2021Article
- Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer.Cancers · 2019Article
- Sub-terahertz vibrational spectroscopy of ovarian cancer and normal control tissue for molecular diagnostic technology.Cancer biomarkers : section A of Disease markers · 2019Article
- Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle.Biomaterials · 2018Article
- Dysregulation of AKT3 along with a small panel of mRNAs stratifies high-grade serous ovarian cancer from both normal epithelia and benign tumor tissues.Genes & cancer · 2017Article
- Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status.Molecular & cellular proteomics : MCP · 2014Article
- Can CA-125 predict lymph node metastasis in epithelial ovarian cancers in Turkish population?Disease markers · 2014Article
- Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.Journal of cancer research and clinical oncology · 2013Article
- Article
- Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma.Results in immunology · 2012Article
- Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array.International journal of cancer · 2012Article
- Article
- In Silico discovery of transcription factors as potential diagnostic biomarkers of ovarian cancer.BMC systems biology · 2011Article
- Article
- Ovarian cancer screening and early detection in the general population.Reviews in obstetrics & gynecology · 2011Article
- Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer.Medical oncology (Northwood, London, England) · 2010Article
- An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.Journal of visualized experiments : JoVE · 2010Article
- Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin.Proteome science · 2010Article
- Proteomics and ovarian cancer: integrating proteomics information into clinical care.Journal of proteomics · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ovarian cancer (OC) is the fourth leading cause of cancer deaths among women in the United States, despite its relatively low incidence of 50 per 100,000. Even though advances in therapy have been made, the OC fatality-to-case ratio remains exceedingly high, due to the lack of accurate tools to diagnose early-stage disease when cure is still possible. The most studied marker for OC, CA125, is only expressed by 50-60% of patients with early stage disease. Large efforts have been deployed to identify novel serum markers, yet no single marker has emerged as a serious competitor for CA125. Various groups are investing in combination approaches to increase the diagnostic value of existing markers, but many markers may still lie in under-explored areas of ovarian cancer biology, such as tumor vasculature environment and post-translational modifications (glycomics).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.